{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:09:44Z","timestamp":1791180584201,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T00:00:00Z","timestamp":1416268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is associated with abnormalities in bone quantity and quality, leading to increased fractures. Recent studies suggest abnormalities of Wnt signaling in animal models of CKD and elevated sclerostin levels in patients with CKD. The goal of this study was to evaluate the effectiveness of anti-sclerostin antibody treatment in an animal model of progressive CKD with low and high parathyroid hormone (PTH) levels. Cy\/+ male rats (CKD) were treated without or with calcium in the drinking water at 25 weeks of age to stratify the animals into high PTH and low PTH groups, respectively, by 30 weeks. Animals were then treated with anti-sclerostin antibody at 100\u2009mg\/kg i.v. weekly for 5 doses, a single 20-\u00b5g\/kg subcutaneous dose of zoledronic acid, or no treatment, and were then euthanized at 35 weeks. As a positive control, the efficacy of anti-sclerostin antibody treatment was also evaluated in normal littermates. The results demonstrated that the CKD animals with high PTH had lower calcium, higher phosphorus, and lower FGF23 compared to the CKD animals with low PTH. Treatment with anti-sclerostin antibody had no effect on any of the biochemistries, whereas zoledronic acid lowered dkk-1 levels. The anti-sclerostin antibody increased trabecular bone volume\/total volume (BV\/TV) and trabecular mineralization surface in animals with low PTH, but not in animals with high PTH. Neither anti-sclerostin antibody nor zoledronic acid improved biomechanical properties in the animals. Cortical porosity was severe in high-PTH animals and was unaffected by either treatment. In contrast, in normal animals treated with anti-sclerostin antibody, there was an improvement in bone volume, cortical geometry, and biomechanical properties. In summary, this is the first study to test the efficacy of anti-sclerostin antibody treatment on animals with advanced CKD. We found efficacy in improving bone properties only when the PTH levels were low. \u00a9 2014 American Society for Bone and Mineral Research<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.2372","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T22:03:43Z","timestamp":1416348223000},"page":"499-509","source":"Crossref","is-referenced-by-count":109,"title":["Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy"],"prefix":"10.1093","volume":"30","author":[{"given":"Sharon M","family":"Moe","sequence":"first","affiliation":[{"name":"Roduebush Veterans Affairs Medical CenterIndianapolisINUSA"},{"name":"Department of MedicineIndiana University School of MedicineIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal X","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of MedicineIndiana University School of MedicineIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell BiologyIndiana University School of MedicineIndianapolisINUSA"},{"name":"Department of MedicineIndiana University School of MedicineIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M","family":"Organ","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell BiologyIndiana University School of MedicineIndianapolisINUSA"},{"name":"Department of MedicineIndiana University School of MedicineIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kneissel","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical ResearchNovartis SwitzerlandBaselSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Kramer","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical ResearchNovartis SwitzerlandBaselSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Vincent H","family":"Gattone","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell BiologyIndiana University School of MedicineIndianapolisINUSA"},{"name":"Department of MedicineIndiana University School of MedicineIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell BiologyIndiana University School of MedicineIndianapolisINUSA"},{"name":"Department of MedicineIndiana University School of MedicineIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,18]]},"reference":[{"key":"2024020319183144100_jbmr2372-bib-0001","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group"},{"issue":"11","key":"2024020319183144100_jbmr2372-bib-0002","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int."},{"issue":"1","key":"2024020319183144100_jbmr2372-bib-0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","article-title":"Chronic kidney disease-mineral-bone disorder: a new paradigm","volume":"14","author":"Moe","year":"2007","journal-title":"Adv Chronic Kidney Dis."},{"issue":"12","key":"2024020319183144100_jbmr2372-bib-0004","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024020319183144100_jbmr2372-bib-0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int."},{"issue":"4","key":"2024020319183144100_jbmr2372-bib-0006","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2024020319183144100_jbmr2372-bib-0007","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1681\/ASN.2007050555","article-title":"The effect of raloxifene treatment in postmenopausal women with CKD","volume":"19","author":"Ishani","year":"2008","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"2024020319183144100_jbmr2372-bib-0008","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020319183144100_jbmr2372-bib-0009","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2215\/CJN.10331012","article-title":"Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients","volume":"8","author":"Sprague","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"2024020319183144100_jbmr2372-bib-0010","doi-asserted-by":"crossref","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","article-title":"PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop","volume":"299","author":"Lavi-Moshayoff","year":"2010","journal-title":"Am J Physiol Renal Physiol."},{"issue":"4","key":"2024020319183144100_jbmr2372-bib-0011","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.bone.2011.06.025","article-title":"Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo","volume":"49","author":"Rhee","year":"2011","journal-title":"Bone."},{"issue":"2","key":"2024020319183144100_jbmr2372-bib-0012","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bone.2012.09.016","article-title":"Effects of PTH on osteocyte function","volume":"54","author":"Bellido","year":"2013","journal-title":"Bone."},{"issue":"1","key":"2024020319183144100_jbmr2372-bib-0013","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ndt\/gfr270","article-title":"Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients","volume":"27","author":"Cejka","year":"2012","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"2024020319183144100_jbmr2372-bib-0014","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med."},{"issue":"5","key":"2024020319183144100_jbmr2372-bib-0015","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4305","article-title":"Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study","volume":"15","author":"Marenzana","year":"2013","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"2024020319183144100_jbmr2372-bib-0016","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.bbrc.2013.10.155","article-title":"Sclerostin deficient mice rapidly heal bone defects by activating beta-catenin and increasing intramembranous ossification","volume":"441","author":"McGee-Lawrence","year":"2013","journal-title":"Biochem Biophys Res Commun."},{"issue":"11","key":"2024020319183144100_jbmr2372-bib-0017","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/jbmr.1984","article-title":"Sclerostin antibody stimulates bone regeneration after experimental periodontitis","volume":"28","author":"Taut","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020319183144100_jbmr2372-bib-0018","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2106\/JBJS.L.00285","article-title":"Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model","volume":"95","author":"Virk","year":"2013","journal-title":"J Bone Joint Surg Am."},{"issue":"1","key":"2024020319183144100_jbmr2372-bib-0019","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.2154","article-title":"Insights into the mechanisms of sclerostin action in regulating bone mass accrual","volume":"29","author":"Williams","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2024020319183144100_jbmr2372-bib-0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2024020319183144100_jbmr2372-bib-0021","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2215\/CJN.06550810","article-title":"Sclerostin and Dickkopf-1 in renal osteodystrophy","volume":"6","author":"Cejka","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"8","key":"2024020319183144100_jbmr2372-bib-0022","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/jbmr.1630","article-title":"Repression of osteocyte Wnt\/beta-catenin signaling is an early event in the progression of renal osteodystrophy","volume":"27","author":"Sabbagh","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2024020319183144100_jbmr2372-bib-0023","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00198-012-2103-x","article-title":"Skeletal effects of zoledronic acid in an animal model of chronic kidney disease","volume":"24","author":"Allen","year":"2013","journal-title":"Osteoporos Int."},{"issue":"6","key":"2024020319183144100_jbmr2372-bib-0024","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000356335","article-title":"Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and\/or calcium treatment","volume":"38","author":"Allen","year":"2013","journal-title":"Am J Nephrol."},{"issue":"2","key":"2024020319183144100_jbmr2372-bib-0025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ki.2008.456","article-title":"A rat model of chronic kidney disease-mineral bone disorder","volume":"75","author":"Moe","year":"2009","journal-title":"Kidney Int."},{"issue":"11","key":"2024020319183144100_jbmr2372-bib-0026","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/jbmr.485","article-title":"The pathophysiology of early-stage chronic kidney disease\u2013mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat","volume":"26","author":"Moe","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2024020319183144100_jbmr2372-bib-0027","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/jbmr.2089","article-title":"A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD","volume":"29","author":"Moe","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020319183144100_jbmr2372-bib-0028","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/ndt\/gfp078","article-title":"R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD)","volume":"24","author":"Moe","year":"2009","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"2024020319183144100_jbmr2372-bib-0029","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020319183144100_jbmr2372-bib-0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmet.2009.12.007","article-title":"Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation","volume":"11","author":"Guo","year":"2010","journal-title":"Cell Metab."},{"issue":"1","key":"2024020319183144100_jbmr2372-bib-0031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S8756-3282(00)00284-2","article-title":"Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation","volume":"27","author":"Hirano","year":"2000","journal-title":"Bone."},{"issue":"5 Suppl","key":"2024020319183144100_jbmr2372-bib-0032","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"6","key":"2024020319183144100_jbmr2372-bib-0033","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2024020319183144100_jbmr2372-bib-0034","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000347031","article-title":"Transglutaminase 2 accelerates vascular calcification in chronic kidney disease","volume":"37","author":"Chen","year":"2013","journal-title":"Am J Nephrol."},{"issue":"5","key":"2024020319183144100_jbmr2372-bib-0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","article-title":"RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2024020319183144100_jbmr2372-bib-0036","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1210\/endo.142.10.8437","article-title":"OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats","volume":"142","author":"Kostenuik","year":"2001","journal-title":"Endocrinology."},{"issue":"8","key":"2024020319183144100_jbmr2372-bib-0037","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","article-title":"Rapid cortical bone loss in patients with chronic kidney disease","volume":"28","author":"Nickolas","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020319183144100_jbmr2372-bib-0038","doi-asserted-by":"crossref","first-page":"e2942","DOI":"10.1371\/journal.pone.0002942","article-title":"Control of bone mass and remodeling by PTH receptor signaling in osteocytes","volume":"3","author":"O'Brien","year":"2008","journal-title":"PLoS One."},{"issue":"41","key":"2024020319183144100_jbmr2372-bib-0039","doi-asserted-by":"crossref","first-page":"29809","DOI":"10.1074\/jbc.M113.485938","article-title":"Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes","volume":"288","author":"Rhee","year":"2013","journal-title":"J Biol Chem."},{"issue":"10","key":"2024020319183144100_jbmr2372-bib-0040","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/jbmr.1962","article-title":"Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH","volume":"28","author":"Li","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"33","key":"2024020319183144100_jbmr2372-bib-0041","doi-asserted-by":"crossref","first-page":"23698","DOI":"10.1074\/jbc.M601000200","article-title":"The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment","volume":"281","author":"Sawakami","year":"2006","journal-title":"J Biol Chem."},{"issue":"11","key":"2024020319183144100_jbmr2372-bib-0042","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/jbmr.145","article-title":"Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms","volume":"25","author":"Jilka","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020319183144100_jbmr2372-bib-0043","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1681\/ASN.2013080818","article-title":"CKD-induced wingless\/integration1 inhibitors and phosphorus cause the CKD\u2013mineral and bone disorder","volume":"25","author":"Fang","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"2024020319183144100_jbmr2372-bib-0044","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2215\/CJN.07670712","article-title":"The relation between renal function and serum sclerostin in adult patients with CKD","volume":"8","author":"Pelletier","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"2024020319183144100_jbmr2372-bib-0045","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1210\/jc.2013-2786","article-title":"Renal elimination of sclerostin increases with declining kidney function","volume":"99","author":"Cejka","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2024020319183144100_jbmr2372-bib-0046","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-10-0699","article-title":"Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls","volume":"163","author":"van Lierop","year":"2010","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2024020319183144100_jbmr2372-bib-0047","doi-asserted-by":"crossref","first-page":"e79721","DOI":"10.1371\/journal.pone.0079721","article-title":"Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease\u2014role of sclerostin","volume":"8","author":"Ferreira","year":"2013","journal-title":"PLoS One."},{"issue":"2","key":"2024020319183144100_jbmr2372-bib-0048","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2372","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/3\/499\/56568668\/jbmr2372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/3\/499\/56568668\/jbmr2372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:53:03Z","timestamp":1710341583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/30\/3\/499-509\/7599294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,18]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,11,18]]},"published-print":{"date-parts":[[2015,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2372","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,3,1]]},"published":{"date-parts":[[2014,11,18]]}}}